SCHOTT

EQS-News: Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda

Retrieved on: 
Wednesday, April 10, 2024
Annual, EUR, Supervisory board, Frankfurt Stock Exchange, CFO, DAX, Election, Messenger, SDAX, Bank statement, Annual general meeting, SCHOTT, Fine chemical

EQS-News: SCHOTT Pharma AG & Co. KGaA

Key Points: 
  • EQS-News: SCHOTT Pharma AG & Co. KGaA
    Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
    The issuer is solely responsible for the content of this announcement.
  • Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
    SCHOTT Pharma's first Annual General Meeting was held virtually on March 14, 2024
    SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, held its first Annual General Meeting today.
  • The Annual General Meeting took place virtually and allowed shareholders to interact directly and ask questions to the Management Board and Supervisory Board.
  • “Holding our first Annual General Meeting marks the next milestone in our capital market history.

EQS-News: SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility

Retrieved on: 
Wednesday, April 10, 2024
Museum, Obesity, Organization, University, Diabetes, Patient, City, Transport, Messenger, Glass, Commerce, Syringe, Wilson Community College, Research Triangle, SCHOTT, Injection, North Carolina State University, Vaccine, Economic development, Borosilicate glass

EQS-News: SCHOTT Pharma AG & Co. KGaA

Key Points: 
  • EQS-News: SCHOTT Pharma AG & Co. KGaA
    SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility
    The issuer is solely responsible for the content of this announcement.
  • SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina
    First U.S. manufacturing facility to fill demand for domestic supply of glass and polymer prefillable syringes that deliver mRNA, GLP-1, and other therapies
    SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site.
  • SCHOTT Pharma a pioneer in pharmaceutical drug containment solutions and delivery systems, will build the first U.S. facility to manufacture prefillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications.
  • On average, more than 25,000 injections per minute are provided to patients worldwide through a product produced by SCHOTT Pharma.

Go-To-Market Success: The Role of Capital Preservation in Life Science Research and Diagnostic Consumable Manufacturing, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 9, 2024
Business, Health, Business development, SCHOTT, Fine chemical

TORONTO, April 9, 2024 /PRNewswire-PRWeb/ -- In this webinar, Patrick Tuohy and James Downs will address a critical question encountered by most life science and diagnostic companies: Should the development and/or manufacturing of products be outsourced or in-sourced? The webinar delves into how a leading solutions provider for microfluidic devices and microarray assays can assist companies in saving capital and reducing time to market by outsourcing their development and manufacturing needs.

Key Points: 
  • In this free webinar, discover strategies for saving capital and reducing time to market in the development and manufacturing of diagnostic and life science consumables.
  • Business leaders in diagnostic and life science companies grapple with the challenging decision of how to produce their products.
  • In this webinar, the expert speakers will explore how life science and diagnostic companies can leverage pilot line capability.
  • Register for this webinar to discover strategies for saving capital and reducing time to market in the development and manufacturer of diagnostic and life science research consumables.

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina

Retrieved on: 
Monday, March 18, 2024
General Health, Manufacturing, Health, Pharmaceutical, Packaging, Museum, Obesity, Organization, University, Diabetes, Patient, City, Transport, Messenger, Glass, Commerce, Syringe, Wilson Community College, Research Triangle, SCHOTT, Injection, North Carolina State University, Multimedia, Vaccine, Economic development

SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site.

Key Points: 
  • SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site.
  • View the full release here: https://www.businesswire.com/news/home/20240318311726/en/
    Many of the US-based pharmaceutical companies use SCHOTT syriQ® prefillable glass syringes as a leading choice for vaccines, biologics, and GLP-1 medications.
  • On average, more than 25,000 injections per minute are provided to patients worldwide through a product produced by SCHOTT Pharma.
  • SCHOTT Pharma partnered with several organizations throughout the project, including the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, the North Carolina General Assembly, the North Carolina Community College System, Commerce’s Division of Workforce Solutions, Wilson County, the City of Wilson, the Wilson Economic Development Council, the North Carolina Biotechnology Center, and the Biomanufacturing Training and Education Center at North Carolina State University.

EQS-News: SCHOTT Pharma reports good start into fiscal year 2024

Retrieved on: 
Wednesday, March 13, 2024
CFO, SCHOTT, DDS, Vaccine, Messenger, Growth, Spacecraft, Syringe, HVS, EUR, Glass, Patient, Drug, Administration, Investment, DCS, Fine chemical

Q1 2024 revenues of EUR 232m; increase of 8% yoy at constant currencies

Key Points: 
  • Q1 2024 revenues of EUR 232m; increase of 8% yoy at constant currencies
    SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, had a good start into the fiscal year 20241.
  • On this basis, we are embarking on another successful year for SCHOTT Pharma,” said Andreas Reisse, CEO of SCHOTT Pharma.
  • In the first quarter of 2024, SCHOTT Pharma achieved several milestones along its strategy of innovation and expansion, demonstrating its commitment to growth.
  • The most important pharma trends that SCHOTT Pharma meets with its products will continue to serve as growth drivers for the company.

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024
DAX, Drug, Diabetes, Obesity, Patient, Frankfurt Stock Exchange, HVS, Glass, Syringe, CFO, DDS, SCHOTT, DCS, Annual, Cancer, Administration, Parkinson's disease, Insulin, Spacecraft, Supervisory board, Investment, SDAX, IPO, EUR, FY, Messenger, Growth, Fine chemical

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.

EQS-News: SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance

Retrieved on: 
Thursday, December 21, 2023
IPO, Texas Homecare, Growth, SDAX, Messenger, EUR, EBITDA, CFO, Administration, Patient, Annual report, FY, DAX, SCHOTT, HVS, Borosilicate glass, Security (finance), Fine chemical

EQS-News: SCHOTT Pharma AG & Co. KGaA

Key Points: 
  • EQS-News: SCHOTT Pharma AG & Co. KGaA
    SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance
    The issuer is solely responsible for the content of this announcement.
  • SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance
    Full set of FY 2023 financial results to be published on January 26, 2024
    SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, closed its fiscal year 20231 with revenues of EUR 899m at the upper end of its guidance.
  • The company’s EBITDA increased in line with revenue to EUR 239m (+9% yoy), enabling SCHOTT Pharma to maintain its high EBITDA margin of 26.6%.
  • As of December 18, 2023, SCHOTT Pharma was included in the SDAX, joining the DAX family for the first time.

Exploring Porous Glass as a Cutting-Edge Substrate for Life Science Applications, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, December 18, 2023
Doctor of Philosophy, Filtration, Research, POC, Business development, Chemistry, DNA, SCHOTT, Ceramic

TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar to explore porous glass innovations' diverse uses in life science research and diagnostics, uncovering unique properties and versatile applications. Designing and manufacturing life science research and diagnostic consumables can be a challenging journey. From selecting the appropriate materials to designing for manufacturing, innovators are faced with endless challenges on their path to commercial success.

Key Points: 
  • In this free webinar, learn about the unique properties of porous glass for various uses in research, diagnostics and other life science applications.
  • The featured speakers will discuss the diverse applications of porous glass, from improving DNA synthesis to serving as a superior alternative in filtration and separation processes.
  • TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar to explore porous glass innovations' diverse uses in life science research and diagnostics, uncovering unique properties and versatile applications.
  • In this webinar, Dr. Bill James, PhD, will share an innovation in porous glass, SCHOTT CoralPor®, that has broad applications across life science.

Solar Cover Glass Market to grow by USD 4.27 billion from 2023 to 2028 | Market is fragmented due to the presence of prominent companies like AGC Inc., Borosil Ltd. and Central Glass Co. Ltd., and many more - Technavio

Retrieved on: 
Monday, November 27, 2023
CSG, Glass, SCHOTT, Koch Industries, Investment, Power, Compagnie Nationale du Rhône, Power station, Corning Inc., USD, AGC Inc., CSG Holding, Growth, International Energy Agency, Information International, Inc., Geography, Life, AGC Glass Europe, Music, Renewable energy, Speciality chemicals

The solar cover glass market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The solar cover glass market is fragmented owing to the presence of many global and regional companies.
  • Download a Free Sample before buying
    AGC Inc. - The company offers solar cover glass such as ultra-low iron solar float glass and ultra-durable solar glass, under its subsidiary AGC Glass Europe SA.
  • The glass market is estimated to grow y USD 99.26 billion at a CAGR of 5.77% between 2022 and 2027.
  • The cellular glass market size is estimated to grow by USD 129.7 million at a CAGR of 4.05% between 2023 and 2028.

EQS-News: Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company

Retrieved on: 
Thursday, December 14, 2023
ISIN, CFO, MDAX, IPO, Growth, DAX, WKN, SCHOTT, SDAX, Frankfurt Stock Exchange, Borosilicate glass, Security (finance), Fine chemical, Frankfurt

EQS-News: SCHOTT Pharma AG & Co. KGaA

Key Points: 
  • EQS-News: SCHOTT Pharma AG & Co. KGaA
    The issuer is solely responsible for the content of this announcement.
  • Andreas Reisse, CEO of SCHOTT Pharma, said: “Following our successful IPO just a little over two months ago, SCHOTT Pharma’s inclusion in the SDAX shows that investors have confidence in our business model and see the potential of our company.
  • The main criterion for the weighting of SDAX shares is market capitalization based on free float (minimum of 10%), which is around 23% for SCHOTT Pharma.
  • The company went public on September 28 this year on the Frankfurt Stock Exchange, marking the largest German IPO of 2023.